A Prospective Post-Marketing Observational Study of Brivaracetam in People With Focal Epilepsy
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2024-11 · 51 (6) · 860-864
DOI: 10.1017/cjn.2023.328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, online erschienen am 27.12.2023. Verfasst von Rayan Yanes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Université de Montréal, Montréal, QC, Canada. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
We evaluated the effectiveness and tolerability of brivaracetam (BRV), an adjunctive antiseizure medication, as a treatment for focal epilepsy in adults. In this prospective study, we enrolled 51 participants from 3 sites across Canada. At 6 months, 68% (26/38) of participants were still taking BRV, among whom 35% (8/23) attained seizure freedom and 48% (11/23) saw their seizure frequency reduced by over 50%. We did not measure any significant change in irritability, quality of life, depression, and anxiety while treated with BRV. Our findings suggest BRV is effective in reducing seizure frequency among adults with focal epilepsy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.
- Department of Neuroscience, Université de Montréal, Montréal, QC, Canada.
- Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
- Division of Neurology, Dalhousie Medical School, Halifax, NS, Canada.
- Division of Neurology, University of Toronto, Toronto, ON, Canada.
- Division of Neurology, University of Calgary, Calgary, AB, Canada.
ORCID-Profile: Joel Neves Briard, Steve Gibbs, Colin Josephson, Mark Keezer
Zitieren
APA
Yanes, R., Briard, J. N., Nguyen, T. J., Sultanem, M., Nguyen, D. K., Gibbs, S., Ikeda, K., Jirsch, J., Josephson, C., Boisse Lomax, L., Cloutier, V., & Keezer, M. (2024). A Prospective Post-Marketing Observational Study of Brivaracetam in People With Focal Epilepsy. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51(6), 860-864. https://doi.org/10.1017/cjn.2023.328
Vancouver
Yanes R, Briard JN, Nguyen TJ, Sultanem M, Nguyen DK, Gibbs S, et al. A Prospective Post-Marketing Observational Study of Brivaracetam in People With Focal Epilepsy. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 2024;51(6):860-864. doi:10.1017/cjn.2023.328
BibTeX
@article{Yanes2024,
author = {Yanes, Rayan and Briard, Joel Neves and Nguyen, Tang-Duc Jeremy and Sultanem, Maya and Nguyen, Dang Khoa and Gibbs, Steve and Ikeda, Kristin and Jirsch, Jeffrey and Josephson, Colin and Boisse Lomax, Lysa and Cloutier, Véronique and Keezer, Mark},
title = {A Prospective Post-Marketing Observational Study of Brivaracetam in People With Focal Epilepsy},
journal = {Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques},
year = {2024},
volume = {51},
number = {6},
pages = {860--864},
doi = {10.1017/cjn.2023.328}
}
EUVIMED